Airway function measurements and the long-term follow-up of survivors of preterm birth with and without chronic lung disease

2006 ◽  
Vol 41 (6) ◽  
pp. 497-508 ◽  
Author(s):  
Indra Narang ◽  
Eugenio Baraldi ◽  
Michael Silverman ◽  
Andrew Bush
2004 ◽  
Vol 37 (S26) ◽  
pp. 106-107 ◽  
Author(s):  
Teresa Bandeira ◽  
Teresa Nunes

2008 ◽  
Vol 93 (1) ◽  
pp. F58-F63 ◽  
Author(s):  
K J Rademaker ◽  
L S de Vries ◽  
C S P M Uiterwaal ◽  
F Groenendaal ◽  
D E Grobbee ◽  
...  

CHEST Journal ◽  
2016 ◽  
Vol 149 (5) ◽  
pp. 1285-1293 ◽  
Author(s):  
Julie Jarand ◽  
J. Paul Davis ◽  
Robert L. Cowie ◽  
Stephen K. Field ◽  
Dina A. Fisher

BMJ Open ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. e053066
Author(s):  
Noor E Simons ◽  
Emilie V J van Limburg Stirum ◽  
Aleid G van Wassenaer-Leemhuis ◽  
Martijn J J Finken ◽  
Cornelieke S H Aarnoudse-Moens ◽  
...  

IntroductionPreterm birth is one of the main problems in obstetrics, and the most important cause of neonatal mortality, morbidity and neurodevelopmental impairment. Multiple gestation is an important risk factor for preterm birth, with up to 50% delivering before 37 weeks. Progesterone has a role in maintaining pregnancy and is frequently prescribed to prevent (recurrent) preterm birth and improve pregnancy outcomes in high-risk patients. However, little is known about its long-term effects in multiple gestations. The objective of this follow-up study is to assess long-term benefits and harms of prenatal exposure to progesterone treatment in multiple gestations on child development.Methods and analysisThis is a follow-up study of a multicentre, double-blind, placebo-controlled randomised trial (AMPHIA trial, ISRCTN40512715). Between 2006 and 2009 women with a multiple gestation were randomised at 16–20 weeks of gestation to weekly injections 250 mg 17α-hydroxyprogesterone caproate or placebo, until 36 weeks of gestation or delivery. The current long-term follow-up will assess all children (n=1355) born to mothers who participated in the AMPHIA trial, at 11–14 years of age, with internationally validated questionnaires, completed by themselves, their parents and their teachers.Main outcomes are child cognition and behaviourAdditional outcomes are death (perinatal and up to age 14), gender identity, educational performance and health-related problems. We will use intention-to-treat analyses comparing experimental and placebo group. To adjust for the correlation between twins, general linear mixed-effects models will be used.Ethics and disseminationAmsterdam UMC MEC provided a waiver for the Medical Research Involving Human Subjects Act (W20_234#20.268). Results will be disseminated through peer-reviewed journals and summaries shared with stakeholders, patients and participants. This protocol is published before analysis of the results.Trial registration numberNL8933.


Author(s):  
Effrosyni D. Manali ◽  
Nadia Nathan ◽  
Caroline Kannengiesser ◽  
Periklis Tomos ◽  
Aurore Coulomb-L’Hermine ◽  
...  

1980 ◽  
Vol 61 (4) ◽  
pp. 9-10
Author(s):  
G. I. Kirshin

The data of long-term follow-up of 130 patients who suffered in childhood with protracted (32) and chronic (98) pneumonia are presented. When examined at the age of 14-30, 23 people were recognized as healthy, in 107 chronic nonspecific lung diseases were revealed, in the formation and course of which viral and bacterial pneumonia transferred in childhood, pathology of pregnancy and childbirth in the mother, tuberculous bronchoadenitis were important; smoking and unfavorable living conditions contributed to the development of severe forms of bronchitis.


Sign in / Sign up

Export Citation Format

Share Document